Melanoma Treatment in China: 2026 Drug Price & Care Guide

• Cost Savings: Systemic melanoma drug costs in China are generally 10% to 25% of US prices.
• Immunotherapy: Domestically approved PD-1 inhibitors (like Toripalimab) cost around $260 per dose, over 30 times less than US equivalents.
• Targeted Therapy: Imatinib for KIT mutations costs a few hundred RMB monthly due to centralized procurement.
• Clinical Focus: Chinese hospitals specialize in acral and mucosal melanoma, offering highly targeted domestic drug combinations.

For international patients researching cross-border medical care, the financial toxicity of late-stage melanoma treatment is a significant burden. China has emerged as a strategic destination not merely for its drastically lower drug costs, but for its unparalleled clinical expertise in specific melanoma subtypes.

While Western oncology centers see predominantly cutaneous (skin) melanoma, Chinese specialists manage the world's highest volume of acral and mucosal melanomas. This unique patient demographic has driven the development of highly effective, proprietary drug combinations that are both clinically advanced and financially accessible.

Melanoma drug prices in China are significantly lower because of government-negotiated centralized procurement and a highly competitive domestic pharmaceutical market. Even though international patients pay out-of-pocket, they still access these nationally unified low retail prices.

Foreign patients traveling to China for medical care do not qualify for Chinese public health insurance reimbursement. However, the self-pay retail prices—known as "procurement prices" (挂网价)—are heavily regulated. The Chinese government negotiates directly with pharmaceutical companies to lower the cost of critical cancer therapies for its population. When international patients pay at official public hospital billing counters, they are charged this exact same baseline rate.

Overall, the systemic treatment costs for melanoma in China range from 10% to 25% of the prices found in the United States. This structural pricing advantage removes the extreme financial pressure associated with long-term immunotherapy and targeted therapy.

Immunotherapy drugs like Toripalimab cost approximately $260 per dose in China compared to over $8,000 in the US, while targeted therapies for KIT mutations cost just hundreds of dollars a month. This stark price difference makes long-term systemic treatment financially viable.

The most striking example of the US-China price gap is Toripalimab (marketed as Tuoyi in China and Loqtorzi in the US). It was China's first domestically approved PD-1 inhibitor and the first specifically approved for melanoma. Recently, it also received FDA approval in the United States for specific indications.

For patients requiring targeted therapy, the cost savings are equally profound. Imatinib, highly effective for KIT-mutated melanoma, has undergone national centralized procurement in China, dropping the monthly supply cost to roughly the equivalent of a standard utility bill. Similar cost dynamics apply to BRAF+MEK inhibitors, which remain significantly cheaper in China than the standard $15,000+ monthly price tags seen in US pharmacies.

Much like the savings detailed in our Lung Cancer Treatment in China: 2026 Drug Price & Care Guide, accessing these medications requires navigating official hospital pathways, but the financial relief is immediate.

Key Takeaway: The exact same molecular compounds, manufactured by regulated pharmaceutical companies, are available at a fraction of the cost. The price difference for Toripalimab alone is over 30 times.

Chinese oncologists treat a high volume of acral and mucosal melanomas, which make up about 65% of cases in China compared to just 6% in the West. This unparalleled clinical experience has led to highly effective, proprietary drug combinations for these specific subtypes.

Melanoma is not a single disease. In Western populations, approximately 90% of cases are cutaneous (skin) melanoma, largely driven by UV exposure. As a result, US and European clinical guidelines are heavily optimized for this specific presentation.

In contrast, the epidemiological profile in Asia is vastly different:

• Acral Melanoma (palms, soles, under nails): Accounts for ~40% of cases in China, vs. ~5% in the West.
• Mucosal Melanoma (nasal, oral, gastrointestinal, gynecological): Accounts for ~25% of cases in China, vs. ~1% in the West.

Because these subtypes have lower BRAF mutation rates and historically poorer responses to single-agent PD-1 inhibitors, Chinese research teams have pioneered combination therapies. A prime example is the use of Toripalimab combined with Axitinib for mucosal melanoma, a regimen that has shown superior objective response rates compared to standard monotherapy and is frequently discussed in international oncology literature.

For international patients—particularly those of Asian descent, or anyone diagnosed with acral/mucosal subtypes or KIT mutations—traveling to China means consulting with specialists who see more cases of your specific disease in a month than many Western oncologists see in a decade.

Prepare a comprehensive medical dossier including your pathology report (with specific melanoma subtype), BRAF/KIT/NRAS genetic testing results, and original DICOM imaging files. Having these ready allows Chinese specialists to provide an accurate remote assessment before you travel.

Before committing to international travel, competent care coordination requires a remote evaluation. Top-tier Chinese oncology centers will review your case to determine if their specialized treatments offer a genuine advantage for your specific molecular profile.

To facilitate this, patients must ensure their records are pristine. The most critical document is the pathology report, which must clearly state the anatomical origin (cutaneous, acral, or mucosal). Equally important is the molecular profiling panel. Because Chinese protocols heavily leverage KIT inhibitors and novel PD-1 combinations, knowing your exact BRAF, NRAS, and KIT status is mandatory for an accurate cost and care estimate.

If your records are exclusively in English, professional medical translation is required before submission to the hospital's international department. Ask China Medical's editorial team strongly advises against relying on automated translation tools for oncology records, as mistranslated staging or genetic markers can alter the entire proposed care route.

Patient safety relies on using official public hospital channels and avoiding gray-market drug sources entirely. To ensure continuity of care, patients must coordinate a transition plan with their home oncologist before starting treatment in China.

The allure of low drug prices unfortunately creates a secondary market of unapproved generics and "daigou" (surrogate purchasing) networks. These avenues present severe legal and health risks. Drugs sourced outside of official hospital pharmacies may be counterfeit, improperly stored, or entirely illegal to possess in both China and the US.

To maintain strict patient safety boundaries, all medications must be prescribed by a licensed Chinese oncologist and dispensed directly from a Top Tier (Class 3 Grade A) hospital pharmacy.

Furthermore, melanoma treatment is rarely a one-time event. Immunotherapy regimens often require infusions every three weeks for a year or more. Patients have two safe options:

1. Relocate temporarily: Secure a medical visa and manage logistics to stay in a serviced apartment near the hospital for the duration of the primary treatment phase.
2. Hybrid care model: Initiate treatment in China to stabilize the disease, and coordinate with a home-country oncologist to continue maintenance therapy. This requires ensuring that the specific drugs used in China have accessible, FDA-approved equivalents back home.

---

Navigating cross-border oncology care requires careful planning, transparent cost estimates, and flawless logistical execution. You do not have to manage the complexities of hospital selection, medical translation, and appointment scheduling alone.

Our team provides professional guidance to make each next step easier, ensuring you have the practical, source-backed context needed to make informed decisions alongside your clinicians.

Ready to explore your options and understand the exact requirements for a remote consultation? Start your inquiry with Ask China Medical today.